Heart Podcast
Cardiovascular risk in patients with chronic kidney disease
Dec 3, 2024
Mark Sarnak, an expert from Tufts University, discusses the intricate relationship between chronic kidney disease (CKD) and cardiovascular risks. He highlights the rising incidence of CKD driven by obesity and diabetes, and the significance of efficient screening. Sarnak delves into the latest guidelines for managing cardiovascular risk in CKD patients, including the use of innovative treatments like SGLT2 inhibitors. He also touches on the complexities of prescribing antiplatelet medications and the future of personalized medicine in cardiovascular care.
21:06
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Chronic kidney disease significantly increases cardiovascular risk, necessitating urgent awareness and better screening strategies for early detection.
- Current treatment options like SGLT2 inhibitors and RAS blockade are essential in managing patients with both chronic kidney disease and cardiovascular issues.
Deep dives
Prevalence and Impact of Chronic Kidney Disease
Chronic kidney disease (CKD) affects approximately 10 to 15% of the population globally, with a significant rise over the past few decades due to obesity, diabetes, and aging. CKD is often silent, meaning many cases go undetected without proper screening strategies. The prevalence of CKD is estimated to be around 700 to 800 million people worldwide. Importantly, the presence of CKD significantly increases the risk of cardiovascular disease independent of other risk factors, highlighting the urgency for awareness and detection.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
